Humana — Feb 11, 2026 release

"We continue to feel good about our consumer-focused strategy and our individual Medicare Advantage membership growth in 2026, which will allow us to build for the future with even better outcomes and experiences." 2 FY 2026 Earnings Guidance Humana introduces its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) of 'at least $8.89', or 'at least $9.00' on an Adjusted basis. The FY 2026 projected guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year 2026, net of mitigation. Diluted earnings per share (a) FY 2026  Guidance FY 2025 GAAP at least $8.89 $9.84  Amortization associated with identifiable intangibles 0.15   0.42  Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) —   4.25  Value creation initiatives (b) —   3.72  Impact of exit of employer group commercial medical products business (b) —   (0.52) Settlement of certain litigation expenses (b) —   0.13  Loss on sale of business (b) —   0.55  Impairment charges (b) —   2.09  Cumulative net tax impact (0.04) (3.34) Adjusted (non-GAAP) – FY 2026 projected (b); FY 2025 reported at least $9.00 $17.14  Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations. Detailed Press Release Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website). Conference Call Humana will host a live question-and-answer session for analysts